Patent application number | Description | Published |
20080248493 | ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES - The present invention relates to methods and kits for detecting an analyte in a test sample using acridinium-9-carboxylate aryl esters. | 10-09-2008 |
20080305512 | ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES - The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention. | 12-11-2008 |
20090017560 | CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME - Provided herein among other things are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed among other things to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease. The method can be employed for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease, but may with time. In one embodiment, the invention also provides a method of determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention. | 01-15-2009 |
20090053736 | Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins - The present invention relates to assays and kits for detecting or quantifying iron metalloprotein in test samples. | 02-26-2009 |
20090053747 | Measurement of Haloperoxidase Activity With Chemiluminescent Detection - The present invention relates to assays and kits for detecting haloperoxidase activity in test samples. | 02-26-2009 |
20090148871 | Interdependent Assays for Detecting Two or More Analytes of Interest in A Test Sample - The present invention relates to interdependent assays and kits for detecting and at least two analytes of interest in a single test sample. | 06-11-2009 |
20090148879 | Stabilizing Compositions, Methods and Kits for Chemiluminescent Assays - The present invention relates to stabilizing compositions, methods and kits for chemiluminescent assays. | 06-11-2009 |
20090162876 | MYELOPEROXIDASE ASSAYS - The present invention relates to methods and kits for determining autoantibodies to myeloperoxidase or a myeloperoxidase fragment and myeloperoxidase or a myeloperoxidase fragment in a test sample. | 06-25-2009 |
20090246800 | IMMUNOASSAY OF ANALYTES IN SAMPLES CONTAINING ENDOGENOUS ANTI-ANALYTE ANTIBODIES - The disclosure provides among other things an assay method that compensates for the presence of endogenous antibodies, e.g., autoantibodies, which might otherwise compromise the measurement of an analyte in a biological sample. In one embodiment, this method entails the use of a two labeled entities: a labeled detection agent and a labeled species-specific antibody, wherein the labeled species-specific antibody is specific for the species from which the biological sample was obtained. Sample analyte is bound by the detection agent and any anti-analyte autoantibodies present in the sample. Analyte bound by autoantibodies is detected via the species-specific antibody, optionally labeled. | 10-01-2009 |
20090263845 | METHOD AND KIT FOR ASSESSING THE SUITABILITY OF ERYTHROCYTES FOR TRANSFUSION - A method of assessing whether or not erythrocytes are suitable for transfusion into a recipient comprising (i) assaying a sample of erythrocytes for free choline, and (ii) comparing the level of free choline in the sample with the level of free choline deemed suitable for transfusion therapies; and a kit for use in such a method comprising at least one reagent for assaying the sample, instructions for conducting the assaying of the sample, and guidelines for assessing the suitability of the erythrocytes for transfusion. | 10-22-2009 |
20090286256 | ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES - The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample. | 11-19-2009 |
20100105150 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL - A method of determining the presence, amount or concentration of at least one autoantibody that reacts with neutrophil gelatinase-associated lipocalin (NGAL), alone or in further combination with a method of determining the concentration of NGAL, which methods can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of a patient and, optionally, modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy; a kit comprising at least one component for assaying a test sample for at least one autoantibody that reacts with NGAL and instructions for assaying; a method of isolating an autoantibody that reacts with NGAL; an isolated autoantibody that reacts with NGAL; and a method for determining the reliability of an NGAL assay result. | 04-29-2010 |
20100178660 | METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES - The present invention relates to methods of detecting hemoglobin in a test sample. These methods can be used to diagnose a subject suffering from a genetic disorder relating to hemoglobin metabolism, to determine the eligibility of a subject to be a blood donor, to determine the age of a stored blood sample or to identify a hemolyzed plasma sample. The present invention also relates to kits for use in the above described methods. | 07-15-2010 |
20100311079 | ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES - The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention. | 12-09-2010 |
20110129818 | ASSAY FOR CARDIAC TROPONIN-T (cTnT) - The present disclosure describes immunoassays for detecting cardiac troponin-T (cTnT) in a test sample, and in particular immunoassays and kits for detecting cTnT in a test sample suspected of containing substances that may interfere with the determination of cTnT, such as heterophilic endogenous antibodies and autoantibodies to cTnT. The methods use more than one capture phase antibody and more than one detection antibody to improve specificity, and provide for the use of humanized immunoreagents to overcome heterophilic antibody interferences. | 06-02-2011 |
20110129854 | ASSAY FOR DIAGNOSIS OF CARDIAC MYOCYTE DAMAGE - Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result. | 06-02-2011 |
20110136103 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte. | 06-09-2011 |
20110136141 | PEPTIDE REAGENTS AND METHOD FOR INHIBITING AUTOANTIBODY ANTIGEN BINDING - The present disclosure provides immunoassays and kits for detection or quantification of an protein of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte. | 06-09-2011 |
20120115244 | MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS - Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and instructions for CMIA, neopterin comprising an Acr-labeled anti-neopterin Ab as a conjugate and instructions for IA, or Acr-labeled neopterin as a tracer and instructions for IA. | 05-10-2012 |
20120202217 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte | 08-09-2012 |
20120270258 | METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES - The present invention relates to methods of detecting hemoglobin in a test sample. These methods can be used to diagnose a subject suffering from a genetic disorder relating to hemoglobin metabolism, to determine the eligibility of a subject to be a blood donor, to determine the age of a stored blood sample or to identify a hemolyzed plasma sample. The present invention also relates to kits for use in the above described methods. | 10-25-2012 |
20120302458 | CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME - Provided herein are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease; for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease; and for determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components useful for performing the methods. | 11-29-2012 |
20130029353 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte | 01-31-2013 |
20140072996 | METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES - The present invention relates to methods of detecting hemoglobin in a test sample. These methods can be used to diagnose a subject suffering from a genetic disorder relating to hemoglobin metabolism, to determine the eligibility of a subject to be a blood donor, to determine the age of a stored blood sample or to identify a hemolyzed plasma sample. The present invention also relates to kits for use in the above described methods. | 03-13-2014 |